Evidence map›Paper›PMID 26032754›Full record

ReviewRheumatology international2015

Polymyalgia rheumatica: strategies for efficient practice and quality assurance.

Michael Schirmer, Christian Dejaco, Bhaskar Dasgupta, Eric L Matteson

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Opioid use in patients with polymyalgia rheumatica.Clinical and experimental rheumatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael SchirmerDepartment of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria. schirmer.michael@icloud.com.
Christian DejacoDivision of Rheumatology and Immunology, Medical University of Graz, Graz, Austria.
Bhaskar DasguptaDepartment of Rheumatology, Southend University Hospital, Westcliff-on-Sea, UK.
Eric L MattesonDivision of Rheumatology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA. matteson.eric@mayo.edu.ORCID http://orcid.org/0000-0001-9208-7809

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.

Indexed as

AlgorithmsCritical PathwaysDecision Support TechniquesGlucocorticoidsHealth Services ResearchHumansPolymyalgia RheumaticaPredictive Value of TestsQuality Assurance, Health CareQuality ImprovementQuality Indicators, Health CareRheumatologyRisk FactorsTreatment OutcomeGlucocorticoidsClassification criteriaDiagnosisOutcomePolymyalgia rheumaticaQuality measuresTreatment

Identifiers

PMID26032754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.